Last reviewed · How we verify

NCT05678413

Role of Paclitaxel in Stricture Urethra

Recruiting now NA Last updated 15 August 2024
What this trial tests

NA trial testing DVIU with paclitaxel injection in Stricture Urethra in 200 participants. Currently enrolling.

Timeline
1 June 2022
Primary endpoint
1 June 2025
1 October 2025

Quick facts

Lead sponsorAl-Azhar University
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment200
Start date1 June 2022
Primary completion1 June 2025
Estimated completion1 October 2025
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Al-Azhar University

Who can join

18 and older, male only, with Stricture Urethra. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Stricture urethra is a common disease and has various causing factors. The most common performed procedure is direct visual internal urethrotomy (DVIU), but unfortunately has a high recurrence rates. Multiple trial were performed to improve the outcomes of DVIU. Various intralesional injections were used. in this trial we will evaluate intralesional paclitaxel injection following DVIU.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Al-Azhar University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05678413.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing